WO2002054080A3 - Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse vasculaire - Google Patents

Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse vasculaire Download PDF

Info

Publication number
WO2002054080A3
WO2002054080A3 PCT/GB2001/005774 GB0105774W WO02054080A3 WO 2002054080 A3 WO2002054080 A3 WO 2002054080A3 GB 0105774 W GB0105774 W GB 0105774W WO 02054080 A3 WO02054080 A3 WO 02054080A3
Authority
WO
WIPO (PCT)
Prior art keywords
vascular response
treatment
vrpis
diagnosis
genes
Prior art date
Application number
PCT/GB2001/005774
Other languages
English (en)
Other versions
WO2002054080A2 (fr
Inventor
Eugene H Herman
Gordon D Holt
Frank D Sistare
Jun Zhang
Original Assignee
Oxford Glycosciences Uk Ltd
Us Gov Health & Human Serv
Eugene H Herman
Gordon D Holt
Frank D Sistare
Jun Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford Glycosciences Uk Ltd, Us Gov Health & Human Serv, Eugene H Herman, Gordon D Holt, Frank D Sistare, Jun Zhang filed Critical Oxford Glycosciences Uk Ltd
Priority to EP01272729A priority Critical patent/EP1368647A2/fr
Priority to AU2002222308A priority patent/AU2002222308A1/en
Publication of WO2002054080A2 publication Critical patent/WO2002054080A2/fr
Publication of WO2002054080A3 publication Critical patent/WO2002054080A3/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2550/00—Electrophoretic profiling, e.g. for proteome analysis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des procédés et des compositions pour le criblage, le diagnostic et le pronostic de la réponse vasculaire, pour le contrôle de l'efficacité du traitement de la réponse vasculaire, pour l'identification des patients les plus susceptibles de répondre à un traitement thérapeutique ou pour la mise au point de médicaments. L'invention porte, notamment, sur le criblage de candidats-médicaments pour l'évaluation de leur capacité à induire une réponse vasculaire. Les caractéristiques associées à la réponse vasculaire (VRF), détectables par électrophorèse bidimensionnelle du sang, du sérum ou du plasma sont décrites. L'invention se rapporte encore à des isoformes protéiques (VRPI) associées à la réponse vasculaire, détectables dans le sang, le sérum ou le plasma, à des préparations comprenant des VRPI isolées, à des anticorps pour les VRPI et à des kits contenant lesdites compositions.
PCT/GB2001/005774 2000-12-29 2001-12-24 Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse vasculaire WO2002054080A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP01272729A EP1368647A2 (fr) 2000-12-29 2001-12-24 Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse vasculaire
AU2002222308A AU2002222308A1 (en) 2000-12-29 2001-12-24 Proteins, genes and their use for diagnosis and treatment of vascular response

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US26038700P 2000-12-29 2000-12-29
US60/260,387 2000-12-29
US25497701P 2001-10-24 2001-10-24
US60/254,977 2001-10-24

Publications (2)

Publication Number Publication Date
WO2002054080A2 WO2002054080A2 (fr) 2002-07-11
WO2002054080A3 true WO2002054080A3 (fr) 2003-09-12

Family

ID=27791427

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2001/005774 WO2002054080A2 (fr) 2000-12-29 2001-12-24 Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse vasculaire

Country Status (3)

Country Link
EP (1) EP1368647A2 (fr)
AU (1) AU2002222308A1 (fr)
WO (1) WO2002054080A2 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2408508A (en) * 2003-11-28 2005-06-01 Astrazeneca Ab Apolipoprotein antibodies
CA2765418A1 (fr) * 2009-06-26 2010-12-29 Five Prime Therapeutics, Inc. Validation de cibles d'anticorps therapeutiques et criblage in vivo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047925A2 (fr) * 1998-03-13 1999-09-23 Oxford Glycosciences (Uk) Ltd. Procedes et compositions pour le diagnostic de la polyarthrite rhumatoide
WO2001069261A2 (fr) * 2000-03-15 2001-09-20 Oxford Glycosciences (Uk) Ltd. Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999047925A2 (fr) * 1998-03-13 1999-09-23 Oxford Glycosciences (Uk) Ltd. Procedes et compositions pour le diagnostic de la polyarthrite rhumatoide
WO2001069261A2 (fr) * 2000-03-15 2001-09-20 Oxford Glycosciences (Uk) Ltd. Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
BLENNOW K ET AL: "CEREBROSPINAL FLUID 'NEURONAL THREAD PROTEIN' COMES FROM SERUM BY PASSAGE OVER THE BLOOD-BRAIN BARRIER", NEURODEGENERATION, ACADEMIC PRESS LTD., LONDON, GB, vol. 4, no. 2, 1995, pages 187 - 193, XP001011872, ISSN: 1055-8330 *
BLOOD COAGULATION & FIBRINOLYSIS: AN INTERNATIONAL JOURNAL IN HAEMOSTASIS AND THROMBOSIS. ENGLAND OCT 1990, vol. 1, no. 4-5, October 1990 (1990-10-01), pages 499 - 503, ISSN: 0957-5235 *
DATABASE MEDLINE [online] October 1990 (1990-10-01), SHAINOFF J R ET AL: "Fibrinogen A alpha and gamma-chain dimers as potential differential indicators of atherosclerotic and thrombotic vascular disease.", XP002224790, Database accession no. NLM1983461 *
LI XIN PING ET AL: "A two-dimensional electrophoresis database of rat heart proteins.", ELECTROPHORESIS, vol. 20, no. 4-5, April 1999 (1999-04-01), pages 891 - 897, XP002224262, ISSN: 0173-0835 *
MANABE T ET AL: "A NONDENATURING PROTEIN MAP OF HUMAN PLASMA PROTEINS CORRELATED WITH A DENATURING POLYPEPTIDE MAP COMBINING TECHNIQUES OF MICRO TWO-DIMENSIONAL GEL ELECTROPHORESIS", ELECTROPHORESIS, WEINHEIM, DE, vol. 20, no. 4/5, April 1999 (1999-04-01), pages 830 - 835, XP001070186, ISSN: 0173-0835 *
MATTILA K M ET AL: "ALTERED BLOOD-BRAIN-BARRIER FUNCTION IN ALZHEIMER'S DISEASE?", ACTA NEUROLOGICA SCANDINAVICA, MUNKSGAARD, COPENHAGEN, DK, vol. 89, no. 3, 1994, pages 192 - 198, XP001011873, ISSN: 0001-6314 *
MENEGATTI MARZIA ET AL: "Identification of four novel polymorphisms in the Aalpha and gamma fibrinogen genes and analysis of association with plasma levels of the protein.", THROMBOSIS RESEARCH, vol. 103, no. 4, 15 August 2001 (2001-08-15), pages 299 - 307, XP002224789, ISSN: 0049-3848 *
RIDKER PAUL M: "Evaluating novel cardiovascular risk factors: Can we better predict heart attacks?", ANNALS OF INTERNAL MEDICINE, vol. 130, no. 11, 1 June 1999 (1999-06-01), pages 933 - 937, XP002224263, ISSN: 0003-4819 *

Also Published As

Publication number Publication date
WO2002054080A2 (fr) 2002-07-11
EP1368647A2 (fr) 2003-12-10
AU2002222308A1 (en) 2002-07-16

Similar Documents

Publication Publication Date Title
WO2002054081A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse renale
WO2002059604A8 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la sclerose en plaques
WO2001075454A3 (fr) Molecules d'acides nucleiques, polypeptides et leurs utilisations pour diagnostic et le traitement de la maladie d'alzheimer notamment
HUP0003533A2 (hu) Interleukin-18-at kötő fehérjék, előállításuk és alkalmazásuk
WO2003028543A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees comprenant le diagnostic et le traitement de la maladie d'alzheimer
FR2751986B1 (fr) Gene implique dans le cadasil, methode de diagnostic et application therapeutique
WO2005100998A3 (fr) Marqueurs membranaires destines a etre utilises pour le diagnostic et le traitement du cancer
ATE353974T1 (de) Verfahren, zusammensetzungen und kits zur identifizierung und überwachung von brustkrebs
WO2002082075A3 (fr) Procede de depistage de maladies dementielles chroniques, et peptides et reactifs de depistage correspondants
WO1996003502A3 (fr) Proteines derivees de muc1 destinees au diagnostic, a l'imagerie et a la therapie du cancer humain
WO2003016464A3 (fr) Sequences d'oligosaccharides specifiques pour le cancer et leur utilisation
WO2001013117A3 (fr) Proteines et genes destines au diagnostic et au traitement du cancer du sein et leur utilisation
WO2000018912A3 (fr) Genes et proteines de cassette de liaison avec atp, destines au diagnostic et au traitement de desordres lipidiques et maladies inflammatoires
WO1999047925A3 (fr) Procedes et compositions pour le diagnostic de la polyarthrite rhumatoide
WO2002046767A3 (fr) Molecules d'acide nucleique, polypeptides et utilisations associees, parmi lesquelles diagnostic et traitement de la maladie d'alzheimer
MXPA02008239A (es) Gen humano de la esquizofrenia.
WO2001062785A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de la schizophrenie
WO2001063294A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de maladies affectives bipolaires (bad) et de depressions unipolaires
WO2001069261A3 (fr) Proteines, genes et leur utilisation dans le diagnostic et le traitement de la demence vasculaire
WO2002054080A3 (fr) Proteines, genes et leur utilisation pour le diagnostic et le traitement de la reponse vasculaire
HUP0101285A2 (hu) Eljárások és készítmények a hepatóma diagnosztizálására
ATE255229T1 (de) Dpi-6, ein therapeutischer biomarker in neurologischen krankheiten
HUP0102444A2 (hu) Protein-C származékok
WO2001096372A3 (fr) Transporteurs de zinc
Cantú Jr et al. The binding effectiveness of anti-r-disintegrin polyclonal antibodies against disintegrins and PII and PIII metalloproteases: An immunological survey of type A, B and A+ B venoms from Mohave rattlesnakes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2001272729

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 2001272729

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2001272729

Country of ref document: EP